Tiltan Pharma Ltd has begun a Phase II clinical trial of its TL-118 drug for the treatment of pancreatic cancer. The trial will include 80 patients at three Israeli hospitals, and will take about a year.
ERZLIYA, Israel and NEW YORK, Jan 30, 2012 (GlobeNewswire via COMTEX) -- IMMUNE Pharmaceuticals, an emerging leader in the development of monoclonal antibody based therapeutics for the treatment of inflammatory diseases and cancer, today announced that the Office of the Chief Scientist (OCS) granted US$1 million (NIS 3.8M) to support two drug development programs...
Israeli scientists, led by Hebrew University Professor, Alexander Vainstein, are using genetically modified tobacco to produce the anti-malaria drug artemisinin.
"Do I Fit?" System was developed by Kivunim team headed by Prof. Itamar Gati, is aimed at assessing the degree to an individual’s career-related preferences fit the core characteristics of an occupation he or she considers. The system currently includes 25 most popular occupations.
Nitrates in drinking water pose serious health problems, but a new low-tech solution from Israel is coming to the rescue.
Hebrew University researchers used plan to produce an effective anti-malaria drug; combating malaria is one of the eight Millennium Development Goals.
Atox Bio will be included as one of the portfolio companies of Integra Holdings, a holding company formed by Yissum, the technology transfer company of the Hebrew University of Jerusalem.
A new monoclonal antibody-based drug development company brings a fresh technological approach and ambitious business model to the Israeli biotech scene.
Technology to be presented today at WATEC, the Water Technologies, Renewable Energy and Environmental Control Exhibition and Conference
Avraham Pharmaceuticals has begun a Phase II clinical trials of its treatment, which combines existing drugs from Teva and Novartis. Yissum Technology has announced that its 30% stake in Avraham Pharmaceuticals (after the latest investment) will be transferred to a new holding company that it founded in the biotech field.
The novel technology has been proven effective in a number of plant species
Yissum, the TTO for the Hebrew University of Jerusalem, has inked agreements with Cincinnati-based Procter & Gamble, the world’s largest consumer goods company, and General Motors.
The first research funded focuses on forecasting of car sales
Mr. Tamir Huberman visited ACE, Tekes and Finnish ICT companies 19th-20th September. As a part of the visit Tamir held a workshop titled “Commercialization of the University’s Intellectual Property – Technology Transfer Practices”. The seminar gathered an audience from the major players of the technology transfer field in Finland.
The new agreement holds new potential for new inventions of the well-established hospital.
The biomarkers discovered by Dr. Karni and the post-doctoral researcher Dr. Regina Golan-Gerstel from the Department of Biochemistry and Molecular Biology are more precise than existing markers, and enable accurate survival prognosis of glioblastoma patients.
BL-7040 has dual activity on both the nervous and immune systems, rendering it highly suitable for treating both neurological diseases and immune system related conditions such as inflammatory or autoimmune diseases. It was invented by HUJI Professor Hermona Soreq.
Agronomie Les chercheurs de l'université de Jérusalem ont révolutionné la culture de la « pomme d'amour » : longue conservation, récolte en branche et variétés miniatures ont été obtenues par sélection classique
The "virtual cane" incorporates several sensors that estimate the distance between the user and the object it is pointed at.
Security: A new approach to video analysis provides a lightning-quick way to scan hours of footage recorded by security cameras
